The next generation of fully human antibodies is here.Learn More
RenMab™: Fully Human Antibody Mouse
The humanized mouse model is the preferred means to produce fully-human antibodies for therapeutics discovery.
Mice that have endogenous antibody genes (heavy and light chains) replaced with human antibody genes can be used to develop humanized antibodies in just one step.
Biocytogen’s RenMab™ Mouse is an antibody-humanized mouse with the most complete antibody genes replacement in the world, which has been designed to greatly simplify and de-risk the antibody development process.
In Situ Gene Replacement
In the RenMab™ Mouse, the parts of the genes that encode for antibody variable domains of H and κ chains are replaced in situ by human sequences using a unique chromosome engineering technique, while the constant domains and critical regulatory elements remain murine.
The length and integrity of humanized antibody gene replacement in the RenMab™ Mouse significantly outperform other existing models.
Robust Immune Response
The RenMab™ Mouse has a normal immune system comparable to that of the wild-type mouse. Because of the higher diversity of its antibody genes, the RenMab™ Mouse has a higher potential for antibody drug development.
The RenMab™ Mouse is the ideal platform for researchers to generate antibody-based drugs with strong specificity, high affinity, and diversity.
Project Integrum: A Revolutionary Knockout Library
We aim to create RenMab™ Mice with over a thousand targets knocked out to cover essentially all non-lethal knockout of targets.Our Pipeline
RenMab ResourcesResource Library
RenMab™ Technical Data SheetDownload
Upcoming EventsAll Events
Benny Yang, PhD
Chief Scientific Officer & Head of Drug Discovery of Biocytogen
May 28, 2020
Fully Human Antibody Therapeutics on RenMab Discovery Platform – A Snapshot of Project Integrum
- January 20-24, 2020
Hilton San Diego Bayfront, San Diego, CA
Peptalk 2020: The Protein Science Week
RenMab™ Mouse and InVivo Efficacy-based Solution for Fully Human Antibody Drug Discovery
Chief Scientific Officer & Director of Antibody Discovery of Biocytogen
- April 16, 2020
In Vivo vs. In Vitro Therapeutic Antibody Discovery
RenMab™ Mouse: a leading platform for fully human antibody generation
Lei Chen, Ph.D.
Senior Director of Antibody Discovery of Biocytogen
News & BlogAll Articles
RenMab™ and RenLite™ Models Featured in GEN Magazine
In the August issue of Genetic Engineering & Biotechnology News, Biocytogen’s RenMab (fully human antibody mouse) and RenLite (common light chain) models are introduced in the article, as well as a case study using RenMab to generate timely monoclonal antibody treatment…Keep Reading